KOEDA, Developer of Next-Generation Anchor Stents for Endoscopic Treatment, Raises New Funds from Mitsubishi UFJ Capital

KOEDA Inc. (Headquarters: Aoba-ku, Sendai, Miyagi Prefecture; CEOs: Toru Okuzono / Masahiro Yagi; hereinafter 'KOEDA'), a developer of next-generation endoscopic treatment devices, announced that it has raised funds through a third-party allocation of shares to Mitsubishi UFJ Capital Co., Ltd. (hereinafter 'MUCAP'), in addition to follow-on investment from existing investor Tohoku University Venture Partners Co., Ltd.

Background and Purpose of Funding: Accelerating Domestic Confirmatory Trials and US Expansion In 2025, KOEDA successfully completed its First in Human (FIH) exploratory clinical trial, the most challenging hurdle in medical device development, proving the safety of its clinical application. The funds raised will be allocated to accelerate the following business progress: 1. Execution of domestic confirmatory clinical trials: Completion of clinical trials for early manufacturing and marketing approval and insurance reimbursement. 2. Strengthening of regulatory approval and Quality Management System (QMS): Building a framework for domestic market launch and US FDA approval application. 3. Preparation for global expansion: Obtaining FDA approval and strengthening intellectual property strategy with an eye on entering the US market, the largest target.

About KOEDA: Transforming Gastrointestinal Medicine with the World's First 'Anchor Technology' KOEDA is a startup developing endoscopic treatment devices (drainage for EUS-GBD/GJ) using the world's first 'anchor technology' for gastrointestinal diseases such as acute cholecystitis. 1. KOEDA's Creativity: Its proprietary 'anchor mechanism' physically fixes organs. This simplifies procedures for gastrointestinal diseases, shortens treatment time, and dramatically reduces the risk of complications. 2. High Technical Reliability: The company has been selected multiple times for public funding such as AMED and JST START, and has received high praise from professional institutions and Key Opinion Leaders (KOLs), including the Japan Biliary Association Award.

Future Outlook: Roadmap Aiming for a 2030 M&A Exit With this funding as a foothold, KOEDA aims to achieve the following milestones and reach an M&A exit to a global MedTech company by 2030. 2027-2028: Obtain domestic manufacturing and marketing approval and launch. Introduction to major hospitals after insurance reimbursement. 2029: Obtain US FDA approval. Start sales in the global market. 2030: Expand indications from gallbladder drainage (EUS-GBD) to gastrojejunostomy (EUS-GJ) and realize business sale (M&A).